<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948324</url>
  </required_header>
  <id_info>
    <org_study_id>87755766</org_study_id>
    <nct_id>NCT00948324</nct_id>
  </id_info>
  <brief_title>Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes</brief_title>
  <official_title>Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate and evaluate the effects of different
      interventions (1.continuous subcutaneous insulin infusion,2.continuous subcutaneous insulin
      infusion combined with rosiglitazone 3.continuous subcutaneous insulin infusion combined with
      metformin,4.continuous subcutaneous insulin infusion combined with α- thioctic acid daily
      injections,) on glycemic control, B-cell function and the remission rate in newly-diagnosed
      type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>beta cell function;fast blood glucose;</measure>
    <time_frame>2011/05</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RSG:CSII combined with three months rosiglitazoneor 4mg QD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MET:CSII combined with metformin 500mg BID-TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSII,ALA,MET,RSG</intervention_name>
    <description>CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.</description>
    <arm_group_label>CSII</arm_group_label>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_label>RSG</arm_group_label>
    <arm_group_label>MET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly diagnosed type 2 diabetes,

        Exclusion Criteria:

          -  received previous antihyperglycaemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yan Bing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Education</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <last_update_submitted>October 1, 2017</last_update_submitted>
  <last_update_submitted_qc>October 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanbing Li</investigator_full_name>
    <investigator_title>Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China</investigator_title>
  </responsible_party>
  <keyword>ype 2 diabetes mellitus, continuous subcutaneous insulin infusion,</keyword>
  <keyword>α-lipoic acid ,rosiglitazone ,metformin，therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

